Reviews/Dry Eye Disease Treatment/Perfluorohexyloctane improves evaporative dry eye signs
Perfluorohexyloctane · DED-PFHO-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across the corpus, perfluorohexyloctane drops repeatedly lowered the amount of surface damage staining on the cornea and lengthened the time the tear film stayed stable in people whose dry eye comes from blocked oil glands. Two large, well-designed trials on different continents measured these objective signs as a main goal and both found the drops did better than a saline control [1][3]. A smaller mechanistic trial showed the drops thicken the tear film and its oily layer, which is how they are thought to work [10], and several follow-along studies and a year-long extension pointed the same way [2][5][8]. The panel saw the direction of benefit as consistent and well supported. The main reservation is that the measured gain over saline is small, and saline is itself an active-ish eye drop rather than an inert dummy, so the size of the benefit is more limited than its reliability.
Two independent double-masked saline-controlled phase 3 RCTs put total corneal fluorescein staining as a co-primary sign endpoint and both favoured perfluorohexyloctane: −2.3 vs −1.1 (difference −1.2, 95% CI −1.7 to −0.8, P<.001) in [1] and −3.8 vs −2.7 (difference −1.14, 95% CI −1.70 to −0.57, P<.001) in [3]. A mechanistic saline-controlled RCT showed the drops increase tear film thickness (6.42%, P=0.0142) and lipid layer thickness [10], matching the proposed evaporation-limiting mode of action. Uncontrolled prospective studies corroborate improvements in tear film breakup time and corneal staining [5][8], and a 52-week open-label extension reports these sign improvements were maintained [2]. The direction of effect on objective signs is consistent across formulations, populations and study designs. The contested point: The division is over magnitude rather than direction: the between-group improvement in corneal staining is modest (approximately −1.2 and −1.14 on the NEI scale in [1] and [3]), and because the comparator is saline, which itself reduced staining (−1.1, −2.7), the incremental sign benefit attributable to the molecule is small. The Sceptic and Synthesist agree the directional signs effect holds; what remains contested is how clinically meaningful that increment is.
All 14 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Dry Eye Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The RCT comparator in [1], [3] and [10] is hypotonic/isotonic saline, not an inert vehicle; saline itself reduced tCFS (-1.1 and -2.7), so the between-group sign effect is modest (tCFS difference approx -1.2 and -1.14 on the NEI scale). Statistically robust but small in clinical magnitude.
Several supportive sign results ([5], [8], [9], [6]) come from uncontrolled or single-arm prospective studies, where regression to the mean and the physical instillation effect are not controlled.
Where it remains uncertain. The comparator is saline, not an inert vehicle, and saline itself reduced staining, so the between-group sign effect is small in magnitude even where it is statistically robust [1][3].
Aleatory
Subgroup estimates vary and some confidence intervals touch or cross zero, e.g. the postmenopausal tCFS LSMD of −1.0 (95% CI −2.0, 0.0) in [12], reflecting patient-to-patient variation in sign response.
Epistemic
Every controlled trial used saline, which is itself active on the ocular surface and reduced staining (−1.1, −2.7), so the drops' effect against a true placebo is unknown [1][3][10].
Inferential
Supportive studies use device-grade F6H8 / EvoTears / NovaTears rather than the NOV03/MIEBO ophthalmic drop of the pivotal RCTs, so pooling across products assumes equivalence [5][6][7][8][9].
The load-bearing papers from a corpus of 14, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT: significant improvement in an objective sign (tCFS) vs saline control.
“Least-squares (LS) mean change from baseline to week 8 was statistically significantly greater for NOV03 compared with saline for both tCFS (-2.3 vs -1.1; LS mean treatment difference, -1.2 [95% confidence interval -1.7 to -0.8]; P < .001)”
Panel auditInternal validity: high · scope of inference: Adults with DED associated with meibomian gland dysfunction over 8 weeks.Key limitations: 8-week horizon · saline (not vehicle) comparator
Demonstrates durability of the signs improvement to 52 weeks.
“improvements in total corneal fluorescein staining and visual analog scale dryness scores observed in GOBI were maintained throughout KALAHARI”
Panel auditInternal validity: low · scope of inference: Patients with DED associated with MGD continuing treatment over 52 weeks.Key limitations: no concurrent control · open-label · no inferential statistics reported for efficacy
Independent second RCT confirming significant tCFS (signs) improvement vs saline.
“changes from baseline at day 57 of tCFS score (mean [SD], -3.8 [2.7] vs -2.7 [2.8]) and eye dryness score (mean [SD], -38.6 [21.9] vs -28.3 [20.8]) in the perfluorohexyloctane group were superior to the control group, with estimated mean differences of -1.14 (95% CI, -1.70 to -0.57; P < .001)”
Panel auditInternal validity: high · scope of inference: Chinese adults with DED associated with MGD over 57 days.Key limitations: 57-day horizon · single-country population · authors note need for independent confirmation
F6H8 significantly increased lipid layer thickness and NIBUT after regular use, tear film signs consistent with the claim.
Panel auditInternal validity: low · scope of inference: DED patients with reduced lipid layer thickness over 12 weeks.Key limitations: no placebo control · within-group inference · small sample
4 of 14 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Converging controlled and prospective primary evidence reliably establishes a directional improvement in signs, while the modest between-group magnitude and saline comparator hold confidence just below the ceiling.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Inert-vehicle controlled trial. Saline is itself active on the ocular surface, so the incremental sign effect of the molecule cannot be separated from a general drop effect [1][3]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-masked RCT with a genuinely inert vehicle arm and total corneal fluorescein staining as the primary sign endpoint.
Open question: How large is the improvement in signs relative to a truly inert vehicle rather than saline? Why it is still open: Every controlled trial in the corpus used saline, which itself reduced corneal staining [1][3][10].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19